{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:03:25Z","timestamp":1794485005882,"version":"4.9.1"},"reference-count":221,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>NPS belonging to the benzodiazepine (BZD) class, e.g., \u2018legal\/designer\nBZDs\u2019\/\u2018research chemicals\u2019, have recently emerged in the drug (mainly online\/virtual) market.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>While certain NPS belonging to the BZD class possess pharmacological profiles similar\nto controlled pharmaceutical BZDs, clinical and pharmacological profiles of current emerging\nBZDs are still not well-described. Therefore, there is a need to increase clinicians\u2019\/public health\nknowledge\/awareness, to incentive harm reduction strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive overview was carried out by using the EMCDDA\/EDND database regularly\nmonitored by our research team, by specifically looking at the \u2018new BZDs\u2019 so far notified.\nFurthermore, given the limitation of peer-reviewed data published so far, a nonparticipant multilingual\nqualitative netnographic study was conducted to obtain further clinical\/pharmacological\/\ntoxicological data, including psychonauts\u2019 online trip reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>First designer BZDs appeared as NPS around 2007. So far, 29 designer BZDs have been\nnotified to the EMCDDA, being some of them extremely powerful, also at lower dosages. They are\nsold as tablets\/powder\/pellets\/capsules\/blotters\/liquids, at very affordable prices, and variably administered.\nSome are also sold on the illicit drugmarket as counterfeit forms of traditional BZDs or\nas either adulterants or diluents in heroin or other synthetic opioids\/cannabinoids. Nowadays, there\nis no guarantee of the quality of designer BZDs composition\/purification and, hence, most NPS\nconsumers may be inadvertently exposed to unsafe and harmful compounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Given the limited information on their pharmacology\/toxicity, variations in dosage,\nonset of effects, combination of substances, potency, and general patient or individual variability,\nthe concomitant use of these substances with other drugs entails several and unpredictable risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x18666200110121333","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T08:16:15Z","timestamp":1578989775000},"page":"809-837","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["\u2018New\/Designer Benzodiazepines\u2019: An Analysis of the Literature and Psychonauts\u2019 Trip Reports"],"prefix":"10.2174","volume":"18","author":[{"given":"Laura","family":"Orsolini","sequence":"first","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Corkery","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vento","sequence":"additional","affiliation":[{"name":"NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University - Rome, School of Medicine and Psychology; Sant\u2019Andrea Hospital, Rome,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"Polyedra, Teramo,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Papanti","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Stahl S.","year":"2013","unstructured":"Stahl S.;  Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis  2013","journal-title":"Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","volume":"34","author":"Tan K.R.","year":"2011","unstructured":"Tan K.R.; Rudolph U.; L\u00fcscher C.; Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci 2011,34(4),188-197","journal-title":"Trends Neurosci"},{"key":"ref=3","author":"Bellantuono C.","year":"2014","unstructured":"Bellantuono C.; Balestrieri M.;  Psicofarmacoterapia 2014","journal-title":"Psicofarmacoterapia"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/cpdd.667","volume":"8","author":"Greenblatt H.K.","year":"2019","unstructured":"Greenblatt H.K.; Greenblatt D.J.; Designer Benzodiazepines: A Review of Published Data and Public Health Significance. Clin Pharmacol Drug Dev 2019,8(3),266-269","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","volume":"32","author":"Fukasawa T.","year":"2007","unstructured":"Fukasawa T.; Suzuki A.; Otani K.; Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007,32(4),333-341","journal-title":"J Clin Pharm Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.mpmed.2015.12.025","volume":"44","author":"Dear J.W.","year":"2016","unstructured":"Dear J.W.; Bateman D.N.; Benzodiazepines. Medicine (Baltimore) 2016,44,145","journal-title":"Medicine (Baltimore)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/dta.1628","volume":"6","author":"Moosmann B.","year":"2014","unstructured":"Moosmann B.; Bisel P.; Auw\u00e4rter V.; Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 2014,6(7-8),757-763","journal-title":"Drug Test Anal"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20236","volume":"14","author":"Moosmann B.","year":"2015","unstructured":"Moosmann B.; King L.A.; Auw\u00e4rter V.; Designer benzodiazepines: A new challenge. World Psychiatry 2015,14(2),248","journal-title":"World Psychiatry"},{"key":"ref=9","unstructured":"United Nations Office on Drugs and Crimes (UNODC). Global\nSMART Update Volume 18, Non-medical use of benzodiazepines:\na growing threat to public health? (2019).   (Accessed Oct 6, 2019)"},{"key":"ref=10","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). European Drug Report 2019: Trends and Developments (2019). Publications Office of the European Union, Luxembourg. (Accessed Oct 6, 2019)"},{"key":"ref=11","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) The misuse of benzodiazepines among high-risk opioid users in Europe (2015). Publications Office of the European Union, Luxembourg.(Accessed Oct 6, 2019)."},{"key":"ref=12","unstructured":"World Health Organization (WHO). Critical Revie Report: flualprazolam.\nExpert Committee on Drug Dependence Forty-Second\nMeeting. Geneva, 21-25 October 2019. (Accessed Oct 15, 2019)"},{"key":"ref=13","first-page":"592","volume":"42","author":"Darbinian T.M.","year":"1979","unstructured":"Darbinian T.M.; Papin A.A.; Vagina M.A.; Petrov O.V.; [Comparative study of the sedative and tranquilizing effect of phenazepama and seduxen and their influence on human evoked brain potentials].  Farmakol Toksikol 1979,42(6),592-597","journal-title":"Farmakol Toksikol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/BF00772264","volume":"13","author":"Zakusov V.V.","year":"1979","unstructured":"Zakusov V.V.; New psychotropic phenazepam preparation. Pharm Chem J (Ussr) 1979,13,1094-1097","journal-title":"Pharm Chem J (Ussr)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF00773022","volume":"18","author":"Sozinov V.A.","year":"1984","unstructured":"Sozinov V.A.; Rudenko O.P.; Zinkovskii V.G.; Golovenko N.Y.; Lisitsyna A.L.; Synthesis of hydrogenated analog of phenazepam. Pharm Chem J (Ussr) 1984,18,721-725","journal-title":"Pharm Chem J (Ussr)"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/15563650902952273","volume":"47","author":"Rafstedt K.","year":"2009","unstructured":"Rafstedt K.; Hult\u00e9n P.; Brusiu K.; Phenazepam as a drug of abuse high frequency of prolonged symptoms. Clin Toxicol (Phila) 2009,47,436-510","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=17","author":"Johnson W.","year":"2010","unstructured":"Johnson W.; Phenazepam in Wisconsin drivers. Annual meeting of the Society of Forensic Toxicologist 2010","journal-title":"Annual meeting of the Society of Forensic Toxicologist"},{"key":"ref=18","first-page":"1320","author":"Baselt R.C.","year":"2011","unstructured":"Baselt R.C.;  Disposition of toxic drugs and chemicals in man 2011,1320-1321","journal-title":"Disposition of toxic drugs and chemicals in man"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"d4207","DOI":"10.1136\/bmj.d4207","volume":"343","author":"Maskell P.D.","year":"2011","unstructured":"Maskell P.D.; Paoli G.D.; Seetohul L.N.; Pounder D.J.; Phenazepam is currently being misused in the UK. BMJ 2011,343,d4207","journal-title":"BMJ"},{"key":"ref=20","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). Country Overview: Moldova (2009). Publications Office of the European Union, Luxembourg.(Accessed Oct 6, 2019)"},{"key":"ref=21","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European\nLegal Database on Drugs (2011). Publications Office of the European Union, Luxembourg. (Accessed Oct 6, 2019)"},{"key":"ref=22","unstructured":"Drugs-Forum. Legal status of phenazepam around the world\n(2019).  (Accessed\nOct 6, 2019)"},{"key":"ref=23","unstructured":"Advisory Council on the Misuse of Drugs (ACMD). Phenazepam\nadvice.  Letter from chair of ACMD to Minister of State for Crime Prevention and ASB reduction (2011). (Accessed Oct 6, 2019)"},{"key":"ref=24","unstructured":"Home Office (2011). Import ban of new 'legal high' phenazepam\nintroduced. Home Office, London. (Accessed Oct 6, 2019)"},{"key":"ref=25","unstructured":"Home Office (2012). Circular: a change to the Misuse of Drugs Act\n1971. Home Office circular 014\/2012 A Change to the Misuse of\nDrugs Act 1971: control of pipradrol-related compounds and\nphenazepam. (Accessed Oct 6, 2019)"},{"key":"ref=26","first-page":"213","volume":"57","author":"Lillsunde P.","year":"2005","unstructured":"Lillsunde P.; Gunnar T.; Drugs and driving: the Finnish perspective. Bull Narc, 2005,57(1 and 2),213-219","journal-title":"Bull Narc,"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.forsciint.2011.05.021","volume":"212","author":"Gjerde H.","year":"2011","unstructured":"Gjerde H.; Christophersen A.S.; Normann P.T.; M\u00f8rland J.; Toxicological investigations of drivers killed in road traffic accidents in Norway during 2006-2008. Forensic Sci Int 2011,212(1-3),102-109","journal-title":"Forensic Sci Int"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.forsciint.2012.02.006","volume":"220","author":"Kriikku P.","year":"2012","unstructured":"Kriikku P.; Wilhelm L.; Rintatalo J.; Hurme J.; Kramer J.; Ojanper\u00e4 I.; Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases and police confiscations. Forensic Sci Int 2012,220(1-3),111-117","journal-title":"Forensic Sci Int"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF03189565","volume":"7","author":"Zherdev V.P.","year":"1982","unstructured":"Zherdev V.P.; Caccia S.; Garattini S.; Ekonomov A.L.; Species differences in phenazepam kinetics and metabolism. Eur J Drug Metab Pharmacokinet 1982,7(3),191-196","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=30","author":"Mykkanen S.","year":"2004","unstructured":"Mykkanen S.; Gunnar T.; Ariniem K.; Lillsunde P.; Krasnova R.; Quantitation of phenazepam in blood by GC-eMS in positive\ndrug-driving cases in Finland. The annual meeting of the Society of\nForensic Toxicologists, Washington DC, USA 2004","journal-title":"The annual meeting of the Society of\nForensic Toxicologists,"},{"key":"ref=31","first-page":"516","volume":"106","author":"Mrozkowska J.","year":"2009","unstructured":"Mrozkowska J.; Vinge E.; Boma C.; Missbruk av fenazepam - ny f\u00f6reteelse i Sverige Abuse of phenazepam - new phenomenon in Sweden. Larkartidningen 2009,106,516-517","journal-title":"Larkartidningen"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jat\/34.8.527","volume":"34","author":"Bailey K.","year":"2010","unstructured":"Bailey K.; Richards-Waugh L.; Clay D.; Gebhardt M.; Mahmoud H.; Kraner J.C.; Fatality involving the ingestion of phenazepam and poppy seed tea. J Anal Toxicol 2010,34(8),527-532","journal-title":"J Anal Toxicol"},{"key":"ref=33","first-page":"13","volume":"29","author":"Volgram J.","year":"1999","unstructured":"Volgram J.; Khdasevitsch T.; A fatal case due to phenazepam. Bull Int Assoc Forensic Toxicologists 1999,29(4),13","journal-title":"Bull Int Assoc Forensic Toxicologists"},{"key":"ref=34","author":"Boone C.","unstructured":"Boone C.; Exotic drug leaves Cherokee teen dead, 3 friends hospitalized.\n(2010). Cherokee County News (20 September 2010).(Accessed Oct 6, 2019)"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"d4207","DOI":"10.1136\/bmj.d4207","volume":"343","author":"Corkery J.M.","year":"2011","unstructured":"Corkery J.M.; Schifano F.; Ghodse H.; UK fatality involving phenazepam. BMJ 2011,343,d4207","journal-title":"BMJ"},{"key":"ref=36","author":"Yip T.","year":"2011","unstructured":"Yip T.; Martin A.; Scott K.S.; Phenazepam abuse in the West of\nScotland 2009-2011. In:  UKIAFT Annual Meeting, Aberdeen, Scotland. 2011","journal-title":"UKIAFT Annual Meeting,"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/hup.2222","volume":"27","author":"Corkery J.M.","year":"2012","unstructured":"Corkery J.M.; Schifano F.; Ghodse A.H.; Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death. Hum Psychopharmacol 2012,27(3),254-261","journal-title":"Hum Psychopharmacol"},{"key":"ref=38","author":"Corkery J.","unstructured":"Corkery J.; Claridge H.; Loi B.; Goodair C.; Schifano F.;  (2013). St George's, University of London.(Accessed\nOct 6, 2019)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00228-012-1361-z","volume":"69","author":"Dargan P.I.","year":"2013","unstructured":"Dargan P.I.; Davies S.; Puchnarewicz M.; Johnston A.; Wood D.M.; First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. Eur J Clin Pharmacol 2013,69(3),361-363","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=40","unstructured":"National Records of Scotland. (2014). Drug-related deaths in Scotland in 2013. (Accessed Oct 6, 2019)"},{"key":"ref=41","author":"Barnsdale L.","unstructured":"Barnsdale L.; Gordon R.; McAuley A.; The National Drug-\nRelated Deaths Database (Scotland) Report: Analysis of deaths occurringin\n2013. (2015).  (Accessed Oct 6, 2019)"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.drugpo.2014.10.010","volume":"26","author":"McAuley A.","year":"2015","unstructured":"McAuley A.; Hecht G.; Barnsdale L.; Thomson C.S.; Graham L.; Priyadarshi S.; Robertson J.R.; Mortality related to novel psychoactive substances in Scotland, 2012: an exploratory study. Int J Drug Policy 2015,26(5),461-467","journal-title":"Int J Drug Policy"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.forsciint.2015.07.033","volume":"254","author":"Shearer K.","year":"2015","unstructured":"Shearer K.; Bryce C.; Parsons M.; Torrance H.; Phenazepam: A review of medico-legal deaths in South Scotland between 2010 and 2014. Forensic Sci Int 2015,254,197-204","journal-title":"Forensic Sci Int"},{"key":"ref=44","first-page":"282","volume":"48","author":"Luzhnikov E.A.","year":"2010","unstructured":"Luzhnikov E.A.; Sukhodolova G.N.; Ostapenko Y.N.; Kovalenko L.A.; Dolginov D.M.; Clinical toxicometry of acute poisonings by fenazepam in older children. Clin Toxicol (Phila) 2010,48,282","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=45","first-page":"74","volume":"1","author":"Aleksandrovskiy Y.A.","year":"2010","unstructured":"Aleksandrovskiy Y.A.; Kraznov V.N.; Neznanov L.V.; Romasenko L.V.; Efficacy of etifoxine versus phenazepam in treatment of patients with adjustment disorders (open-label randomized controlled trial). Russian J Psychiatry 2010,1,74-78","journal-title":"Russian J Psychiatry"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.psym.2014.05.018","volume":"56","author":"Ali A.","year":"2015","unstructured":"Ali A.; Jerry J.M.; Khawam E.A.; Delirium induced by a new synthetic legal intoxicating drug: phenazepam. Psychosomatics 2015,56(4),414-418","journal-title":"Psychosomatics"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00835494","volume":"89","author":"Bogatski\u012d A.V.","year":"1980","unstructured":"Bogatski\u012d A.V.; Golovenko N.Ia.; Zin\u2019kovski\u012d V.G.; [Intrahepatic\ncirculation of 14C-phenazepam and its metabolites in albino rats].  Biull Eksp Biol Med 1980,89(1),27-29","journal-title":"Biull Eksp Biol Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/BF02506568","volume":"32","author":"Kopanitsa M.V.","year":"2000","unstructured":"Kopanitsa M.V.; Zbarska S.M.; Boychuk Y.; Krishtal O.A.; Modulation of GABA-activated currents by phenazepam and its metabolites in isolated rat Purkinje neurons. Neurophysiology 2000,32(3),192","journal-title":"Neurophysiology"},{"key":"ref=49","first-page":"83","author":"Dorofeyeva O.A.","year":"2010","unstructured":"Dorofeyeva O.A.; Syunyakov S.A.; Neznamov G.G.;  Comparative analysis of different phenazepam formulationsRegional congress of the World Psychiatric Association 2010,83","journal-title":"Comparative analysis of different phenazepam formulationsRegional congress of the World Psychiatric Association"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jflm.2011.12.014","volume":"19","author":"Maskell P.D.","year":"2012","unstructured":"Maskell P.D.; De Paoli G.; Nitin Seetohul L.; Pounder D.J.; Phenazepam: the drug that came in from the cold. J Forensic Leg Med 2012,19(3),122-125","journal-title":"J Forensic Leg Med"},{"key":"ref=51","unstructured":"Bluelight.org (Accessed Oct 6, 2019)."},{"key":"ref=52","unstructured":"Erowid.org (Accessed Oct 6, 2019)"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1023\/A:1017519731950","volume":"130","author":"Golovenko N.Y.","year":"2000","unstructured":"Golovenko N.Y.; Kravchenko I.A.; Zin\u2019kovskii V.G.; Andronati S.A.; Aleksandrova A.I.; Ovcharenko N.V.; Larionov V.B.; Biokinetics of transdermal therapeutic medicinal form of phenazepam. Bull Exp Biol Med 2000,130(12),1153-1155","journal-title":"Bull Exp Biol Med"},{"key":"ref=54","unstructured":"Drugs-Forum.com. (Accessed Oct 6, 2019)"},{"key":"ref=55","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). EMCDDA\u2013Europol 2007. Annual Report on the Implementation of Council Decision 2005\/387\/JHA, 2007. Lisbon, Portugal,(Accessed Oct 6, 2019)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/dta.349","volume":"4","author":"Couch R.A.","year":"2012","unstructured":"Couch R.A.; Madhavaram H.; Phenazepam and cannabinomimetics sold as herbal highs in New Zealand. Drug Test Anal 2012,4(6),409-414","journal-title":"Drug Test Anal"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11419-012-0173-2","volume":"31","author":"Lee C.","year":"2013","unstructured":"Lee C.; Lee H.; Pyo J.; Jo J.; Lee J.; Choi H.; Kim S.; Seon R.; Yonghoon H.; Bang P.; Hwang H.; Choe S.; Jung J.H.; Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl)indole. Forensic Toxicol 2013,31(2),187-196","journal-title":"Forensic Toxicol"},{"key":"ref=58","unstructured":"Tripsit Http(Accessed Oct 6, 2019)"},{"key":"ref=59","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). EMCDDA\u2013Europol 2011. Annual Report on the Implementation of Council Decision 2005\/387\/JHA, 2011. Lisbon, Portugal (Accessed\nOct 6, 2019)."},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00280074","volume":"40","author":"Fracasso C.","year":"1991","unstructured":"Fracasso C.; Confalonieri S.; Garattini S.; Caccia S.; Single and multiple dose pharmacokinetics of etizolam in healthy subjects. Eur J Clin Pharmacol 1991,40(2),181-185","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.forsciint.2008.08.012","volume":"182","author":"Nakamae T.","year":"2008","unstructured":"Nakamae T.; Shinozuka T.; Sasaki C.; Ogamo A.; Murakami-Hashimoto C.; Irie W.; Terada M.; Nakamura S.; Furukawa M.; Kurihara K.; Case report: Etizolam and its major metabolites in two unnatural death cases. Forensic Sci Int 2008,182(1-3),e1-e6","journal-title":"Forensic Sci Int"},{"key":"ref=62","unstructured":"National Records of Scotland (2019). Table SUB2 - Substances\nwhich were reported for drug-related deaths on the basis of the Office\nfor National Statistics (ONS) \u2018wide\u2019 definition,  Scotland, 2000 to 2018. 16 July, Edinburgh: National Records of Scotland. Available at: (Accessed 6 October\n2019)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11419-013-0187-4","volume":"31","author":"Moosmann B.","year":"2013","unstructured":"Moosmann B.; Hutter M.; Huppertz L.M.; Ferlaino S.; Redlingsh\u00f6fer L.; Auw\u00e4rter V.; Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 2013,31(2),263-271","journal-title":"Forensic Toxicol"},{"key":"ref=64","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). EMCDDA-Europol 2012. Annual Report on the Implementation\nof Council Decision 2005\/387\/JHA, 2012.  Lisbon, Portugal, (Accessed\nOct 6, 2019)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1021\/jo01058a010]","volume":"27","author":"Sternbach L.H.","year":"1962","unstructured":"Sternbach L.H.; Fryer R.Y.; Metlesics W.; Reeder E.; Sach G.; Saucy G.; Stempel G.; Quinazolines and 1,4-Benzodiazepines. VI.1a Halo-, Methyl-, and Methoxy-substituted 1,3-Dihydro-5-phenyl-2H-1,4- benzodiazepin-2-ones1b,c. J Org Chem 1962,27,3788","journal-title":"J Org Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1021\/jm051185t","volume":"49","author":"Carter M.C.","year":"2006","unstructured":"Carter M.C.; Alber D.G.; Baxter R.C.; Bithell S.K.; Budworth J.; Chubb A.; Cockerill G.S.; Dowdell V.C.L.; Henderson E.A.; Keegan S.J.; Kelsey R.D.; Lockyer M.J.; Stables J.N.; Wilson L.J.; Powell K.L.; 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. J Med Chem 2006,49(7),2311-2319","journal-title":"J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2391","author":"Koch K.","year":"2018","unstructured":"Koch K.; Auw\u00e4rter V.; Hermanns-Clausen M.; Wilde M.; Neukamm M.A.; Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. Drug Test Anal 2018","journal-title":"Drug Test Anal"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/dta.2003","volume":"9","author":"Pettersson Bergstrand M.","year":"2017","unstructured":"Pettersson Bergstrand M.; Helander A.; Hansson T.; Beck O.; Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test Anal 2017,9(4),640-645","journal-title":"Drug Test Anal"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/15563650.2018.1506130","volume":"57","author":"B\u00e4ckberg M.","year":"2019","unstructured":"B\u00e4ckberg M.; Pettersson Bergstrand M.; Beck O.; Helander A.; Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. Clin Toxicol (Phila) 2019,57(3),203-212","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/15563650.2018.1510502","volume":"57","author":"Carpenter J.E.","year":"2019","unstructured":"Carpenter J.E.; Murray B.P.; Dunkley C.; Kazzi Z.N.; Gittinger M.H.; Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017. Clin Toxicol (Phila) 2019,57(4),282-286","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1021\/acs.joc.9b01433","volume":"84","author":"Ligon E.S.","year":"2019","unstructured":"Ligon E.S.; Nawyn J.; Jones L.V.; Allred B.M.; Reinhardt D.V.; France S.; Synthesis of Flubromazepam Positional Isomers for Forensic Analysis. J Org Chem 2019,84(16),10280-10291","journal-title":"J Org Chem"},{"key":"ref=72","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). EMCDDA-Europol, 2013.  Annual Report on the Implementation of Council Decision 2005\/387\/JHA, 2013. Lisbon, Portugal.(Accessed Oct 6, 2019)"},{"key":"ref=73","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2387","author":"Manchester K.R.","year":"2018","unstructured":"Manchester K.R.; Maskell P.D.; Waters L.; Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances. Drug Test Anal 2018","journal-title":"Drug Test Anal"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1021\/jo01058a009","volume":"27","author":"Sternbach L.H.","year":"1962","unstructured":"Sternbach L.H.; Fryer R.I.; Metlesics W.; Sach G.; Stempel A.; Quinazolines and 1,4-Benzodiazepines. V. o-Aminobenzophenones. J Org Chem 1962,27(11),3781-3788","journal-title":"J Org Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0024-3205(79)90484-3","volume":"25","author":"Babbini M.","year":"1979","unstructured":"Babbini M.; Gaiardi M.; Bartoletti M.; Anxiolytic versus sedative properties in the benzodiazepines series: differencies in structure activity relationships. Life Sci 1979,25(1),15-22","journal-title":"Life Sci"},{"key":"ref=76","author":"Sternbach L.H.","year":"1968","unstructured":"Sternbach L.H.; Randall L.O.; Banziger R.; Lehr H.;  Structure activity relationships in the 1,3-benzodiazepine series Drugs Affecting the Central Nervous System 1968","journal-title":"Structure activity relationships in the 1,3-benzodiazepine series Drugs Affecting the Central Nervous System"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0028-3908(84)90195-3","volume":"23","author":"Bradley C.M.","year":"1984","unstructured":"Bradley C.M.; Nicholson A.N.; Activity of the chloro- and triazolo-benzodiazepines. Behavioural studies in the monkey (Macaca mulatta). Neuropharmacology 1984,23(3),327-331","journal-title":"Neuropharmacology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/jm00158a004","volume":"29","author":"Cho M.J.","year":"1986","unstructured":"Cho M.J.; Sethy V.H.; Haynes L.C.; Sequentially labile water soluble prodrugs of alprazolam. J Med Chem 1986,29(8),1346-1350","journal-title":"J Med Chem"},{"key":"ref=79","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol, 2014. Annual Report on the Implementation of Council Decision 2005\/387\/JHA, 2014. Lisbon, Portugal.Accessed Oct 6, 2019."},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejphar.2009.01.021","volume":"606","author":"Thibaut J.P.","year":"2009","unstructured":"Thibaut J.P.; Monteiro L.M.; Leite L.C.; Menezes C.M.; Lima L.M.; No\u00ebl F.; The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors. Eur J Pharmacol 2009,606(1-3),9-16","journal-title":"Eur J Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1208\/s12248-016-0040-x","volume":"19","author":"Vikingsson S.","year":"2017","unstructured":"Vikingsson S.; Wohlfarth A.; Andersson M.; Gr\u00e9en H.; Roman M.; Josefsson M.; Kugelberg F.C.; Kronstrand R.; Identifying Metabolites of meclonazepam by high-resolution mass spectrometry using human liver microsomes, hepatocytes, a mouse model, and authentic urine samples. AAPS J 2017,19(3),736-742","journal-title":"AAPS J"},{"key":"ref=82","first-page":"617","volume":"55","author":"Baard A.P.","year":"1979","unstructured":"Baard A.P.; Sommers D.K.; Honiball P.J.; Fourie E.D.; du Toit L.E.; Preliminary results in human schistosomiasis with Ro 11-3128. S Afr Med J 1979,55(16),617-618","journal-title":"S Afr Med J"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/BF00431795","volume":"87","author":"Ansseau M.","year":"1985","unstructured":"Ansseau M.; Doumont A.; Thiry D.; von Frenckell R.; Collard J.; Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. Psychopharmacology (Berl) 1985,87(2),130-135","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00436-009-1546-2","volume":"105","author":"Abdul-Ghani R.A.","year":"2009","unstructured":"Abdul-Ghani R.A.; Loutfy N.; Hassan A.; Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. Parasitol Res 2009,105(4),899-906","journal-title":"Parasitol Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF00547377","volume":"29","author":"O\u2019Boyle C.","year":"1985","unstructured":"O\u2019Boyle C.; Lambe R.; Darragh A.; Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam. Eur J Clin Pharmacol 1985,29(1),105-108","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0378-4347(85)80105-5","volume":"338","author":"Coassolo P.","year":"1985","unstructured":"Coassolo P.; Aubert C.; Cano J.P.; Plasma determination of 3-methylclonazepam by capillary gas chromatography. J Chromatogr A 1985,338(2),347-355","journal-title":"J Chromatogr A"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1093\/jat\/bky012","volume":"42","author":"Ameline A.","year":"2018","unstructured":"Ameline A.; Richeval C.; Gaulier J.M.; Raul J.S.; Kintz P.; Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J Anal Toxicol 2018,42(6),e58-e60","journal-title":"J Anal Toxicol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11419-015-0277-6","volume":"33","author":"Huppertz L.M.","year":"2015","unstructured":"Huppertz L.M.; Bisel P.; Westphal F.; Franz F.; Auw\u00e4rter V.; Moosmann B.; Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicol 2015,33,388-395","journal-title":"Forensic Toxicol"},{"key":"ref=89","author":"Abe M.","year":"1988","unstructured":"Abe M.; Mikashima H.; Moriwaki M.; Tahara T.;  Thieno(- triazolo)diazepine compound and medicinal application of the same Patent WO1988009333A1, 1988"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/dta.2203","volume":"10","author":"Huppertz L.M.","year":"2018","unstructured":"Huppertz L.M.; Moosmann B.; Auw\u00e4rter V.; Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 2018,10(1),206-211","journal-title":"Drug Test Anal"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/dta.2146","volume":"9","author":"Noble C.","year":"2017","unstructured":"Noble C.; Mardal M.; Bjerre H.N.; Stybe J.S.; Linnet K.; In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. Drug Test Anal 2017,9(8),1182-1191","journal-title":"Drug Test Anal"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.forsciint.2016.10.021","volume":"274","author":"Wohlfarth A.","year":"2017","unstructured":"Wohlfarth A.; Vikingsson S.; Roman M.; Andersson M.; Kugelberg F.C.; Green H.; Kronstrand R.; Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. Forensic Sci Int 2017,274,55-63","journal-title":"Forensic Sci Int"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"133","DOI":"10.9740\/mhc.2019.05.133","volume":"9","author":"Bohnenberger K.","year":"2019","unstructured":"Bohnenberger K.; Liu M.T.; Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil. Ment Health Clin 2019,9(3),133-137","journal-title":"Ment Health Clin"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","volume":"54","author":"\u0141ukasik-G\u0142\u0119bocka M.","year":"2016","unstructured":"\u0141ukasik-G\u0142\u0119bocka M.; Sommerfeld K.; Te\u017cyk A.; Zieli\u0144ska-Psuja B.; Panie\u0144ski P.; \u017baba C.; Flubromazolam--A new life threatening designer benzodiazepine. Clin Toxicol (Phila) 2016,54(1),66-68","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11419-016-0338-5","volume":"35","author":"Katselou M.","year":"2017","unstructured":"Katselou M.; Papoutsis I.; Nikolaou P.; Spiliopoulou C.; Athanaselis S.; Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicol 2017,35(1),1-10","journal-title":"Forensic Toxicol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1021\/jm00293a015","volume":"14","author":"Hester J.B.","year":"1971","unstructured":"Hester J.B.; Rudzik A.D.; Kamdar B.V.; 6-phenyl-4H-s triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity. J Med Chem 1971,14(11),1078-1081","journal-title":"J Med Chem"},{"key":"ref=97","unstructured":"Advisory Council on the Misuse of Drugs (ACMD). Circular 008\/2017: a Change to the Misuse of Drugs Act 1971 to Control U- 47,700, Twelve Methylphenidate Related Substances and Sixteen \u2018designer\u2019 Benzodiazepines (Accessed Oct 6, 2019)"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"30046","DOI":"10.1016\/j.psym.2019.02.007","volume":"14S0033-3182","author":"Shapiro A.P.","year":"2019","unstructured":"Shapiro A.P.; Krew T.S.; Vazirian M.; Jerry J.; Sola C.; Novel ways to acquire designer benzodiazepines: a case report and discussion of the changing role of the internet. Psychosomatics, 2019,14S0033-3182(19),30046-5","journal-title":"Psychosomatics,"},{"key":"ref=99","first-page":"89","author":"Robertson M.","year":"2001","unstructured":"Robertson M.; Raymon L.;  Rohypnol VR and other benzodiazepines Drug-facilitated sexual assault: a forensic handbook; LeBeau, MA 2001,89-106","journal-title":"Rohypnol VR and other benzodiazepines Drug-facilitated sexual assault: a forensic handbook; LeBeau, MA"},{"key":"ref=100","first-page":"463","volume":"27","author":"DeVane C.L.","year":"1991","unstructured":"DeVane C.L.; Ware M.R.; Lydiard R.B.; Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull 1991,27(4),463-473","journal-title":"Psychopharmacol Bull"},{"key":"ref=101","author":"Bird M.","unstructured":"Bird M.; Abuse potential of adinazolam: A comparison with diazepam,\nlorazepam and placebo. In:  Problems of Drug Dependence\n1987, Proceedings of the 49th Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph(81)","journal-title":"Problems of Drug Dependence\n1987,"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.2042-7158.1984.tb04449.x","volume":"36","author":"Sethy V.H.","year":"1984","unstructured":"Sethy V.H.; Collins R.J.; Daniels E.G.; Determination of biological activity of adinazolam and its metabolites. J Pharm Pharmacol 1984,36(8),546-548","journal-title":"J Pharm Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jat\/17.7.427","volume":"17","author":"Fraser A.D.","year":"1993","unstructured":"Fraser A.D.; Isner A.F.; Bryan W.; Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC. J Anal Toxicol 1993,17(7),427-431","journal-title":"J Anal Toxicol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/0028-3908(83)90200-9","volume":"22","author":"Lahti R.A.","year":"1983","unstructured":"Lahti R.A.; Sethy V.H.; Barsuhn C.; Hester J.B.; Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983,22(11),1277-1282","journal-title":"Neuropharmacology"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0304-3940(85)90410-0","volume":"61","author":"File S.E.","year":"1985","unstructured":"File S.E.; Pellow S.; Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites. Neurosci Lett 1985,61(1-2),115-119","journal-title":"Neurosci Lett"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1177\/0091270004269105","volume":"45","author":"Venkatakrishnan K.","year":"2005","unstructured":"Venkatakrishnan K.; Culm K.E.; Ehrenberg B.L.; Harmatz J.S.; Corbett K.E.; Fleishaker J.C.; Greenblatt D.J.; Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol 2005,45(5),529-537","journal-title":"J Clin Pharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00004714-198706000-00010","volume":"7","author":"Dunner D.","year":"1987","unstructured":"Dunner D.; Myers J.; Khan A.; Avery D.; Ishiki D.; Pyke R.; Adinazolam--a new antidepressant: findings of a placebo controlled, double-blind study in outpatients with major depression. J Clin Psychopharmacol 1987,7(3),170-172","journal-title":"J Clin Psychopharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.2042-7158.1998.tb06859.x","volume":"50","author":"Venkatakrishnan K.","year":"1998","unstructured":"Venkatakrishnan K.; von Moltke L.L.; Duan S.X.; Fleishaker J.C.; Shader R.I.; Greenblatt D.J.; Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol 1998,50(3),265-274","journal-title":"J Pharm Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bpa.2018.06.007","volume":"32","author":"Cornett E.M.","year":"2018","unstructured":"Cornett E.M.; Novitch M.B.; Brunk A.J.M.; Davidson K.S.; Menard B.L.; Urman R.D.; Kaye A.D.; New benzodiazepines for sedation. Best Pract Res Clin Anaesthesiol 2018,32(2),149-164","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref=110","unstructured":"European Monitoring Centre for Drugs and Drug Addiction\n(EMCDDA). EMCDDA-Europol, 2015.  Annual Report on the Implementation of Council Decision 2005\/387\/JHA (2016). Lisbon, Portugal. (Accessed Oct 6, 2019)"},{"key":"ref=111","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2383","author":"Dowling G.","year":"2018","unstructured":"Dowling G.; Kavanagh P.V.; Eckhardt H.G.; Twamley B.; Hessman G.; McLaughlin G.; O\u2019Brien J.; Brandt S.D.; An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: The microscale syntheses of nitrazolam and clonazolam for use as reference materials, utilizing polymer-supported reagents. Drug Test Anal [Epub a head of print]. 2018","journal-title":"Drug Test Anal"},{"key":"ref=112","author":"Hester J.B.","unstructured":"Hester J.B.; \"Patent US3987052 - 6-Phenyl-4H-striazolo[\n4,3a][1,4]benzodiazepines.\u201d (1976). (Accessed Oct\n6, 2019)."},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.toxac.2016.03.053","volume":"28","author":"Chaslot M.","year":"2016","unstructured":"Chaslot M.; El Balkhi S.; Robin T.; Morichon J.; Picard N.; Saint\u2010Marcoux F.; Exploration des m\u00e9tabolites de 8 benzodiaz\u00e9pines de synth\u00e8se. Toxicol Anal Clin 2016,28(2),S32","journal-title":"Toxicol Anal Clin"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.forsciint.2016.09.006","volume":"268","author":"H\u00f8iseth G.","year":"2016","unstructured":"H\u00f8iseth G.; Tuv S.S.; Karinen R.; Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Sci Int 2016,268,35-38","journal-title":"Forensic Sci Int"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00216-016-9439-6","volume":"408","author":"Meyer M.R.","year":"2016","unstructured":"Meyer M.R.; Bergstrand M.P.; Helander A.; Beck O.; Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem 2016,408(13),3571-3591","journal-title":"Anal Bioanal Chem"},{"key":"ref=116","unstructured":"Reddit.com (Accessed Oct 7, 2019)"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/dta.2099","volume":"9","author":"Kintz P.","year":"2017","unstructured":"Kintz P.; Richeval C.; Jamey C.; Ameline A.; Allorge D.; Gaulier J.M.; Raul J.S.; Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. Drug Test Anal 2017,9(7),1026-1033","journal-title":"Drug Test Anal"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/jms.3840","volume":"51","author":"Moosmann B.","year":"2016","unstructured":"Moosmann B.; Bisel P.; Franz F.; Huppertz L.M.; Auw\u00e4rter V.; Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. J Mass Spectrom 2016,51(11),1080-1089","journal-title":"J Mass Spectrom"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jpba.2018.02.032","volume":"153","author":"Mortel\u00e9 O.","year":"2018","unstructured":"Mortel\u00e9 O.; Vervliet P.; Gys C.; Degreef M.; Cuykx M.; Maudens K.; Covaci A.; van Nuijs A.L.N.; Lai F.Y.; In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 2018,153,158-167","journal-title":"J Pharm Biomed Anal"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1734-1140(11)70628-4","volume":"63","author":"Schukin S.I.","year":"2011","unstructured":"Schukin S.I.; Zinkovsky V.G.; Zhuk O.V.; Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice. Pharmacol Rep 2011,63(5),1093-1100","journal-title":"Pharmacol Rep"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jat\/bkt075","volume":"37","author":"Kerrigan S.","year":"2013","unstructured":"Kerrigan S.; Mellon M.B.; Hinners P.; Detection of phenazepam in impaired driving. J Anal Toxicol 2013,37(8),605-610","journal-title":"J Anal Toxicol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/dta.1790","volume":"7","author":"Crichton M.L.","year":"2015","unstructured":"Crichton M.L.; Shenton C.F.; Drummond G.; Beer L.J.; Seetohul L.N.; Maskell P.D.; Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. Drug Test Anal 2015,7(10),926-936","journal-title":"Drug Test Anal"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/BF00765846","volume":"14","author":"Ekonomov A.L.","year":"1980","unstructured":"Ekonomov A.L.; Zherdev V.P.; Method of quantitative gas-chromatographic determination of phenazepam and its metabolite 3-hydroxyphenazepam in plasma. Pharm Chem J 1980,14,579-582","journal-title":"Pharm Chem J"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1023\/A:1021503417490","volume":"134","author":"Golovenko N.Y.","year":"2002","unstructured":"Golovenko N.Y.; Larionov V.B.; Kravchenko I.A.; Ovcharenko N.V.; Aleksandrova A.I.; Biokinetics of transdermal 3-hydroxyphenazepam. Bull Exp Biol Med 2002,134(3),254-256","journal-title":"Bull Exp Biol Med"},{"key":"ref=125","first-page":"3","volume":"77","author":"Voronina T.A.","year":"2014","unstructured":"Voronina T.A.; Larionov V.B.; Golovenko N.Ia.; Nerobkova L.N.; Peculiarities of hypnotic effect and pharmacokinetics of hemisuccinate 3-hydroxyphenazepam (levana). Eksp Klin Farmakol 2014,77(1),3-6","journal-title":"Eksp Klin Farmakol"},{"key":"ref=126","unstructured":"World Health Organization (WHO)- Expert Committee on Drug Dependence (ECDD) 2015"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jflm.2015.08.017","volume":"36","author":"Lomas E.C.","year":"2015","unstructured":"Lomas E.C.; Maskell P.D.; Phenazepam: More information coming in from the cold. J Forensic Leg Med 2015,36,61-62","journal-title":"J Forensic Leg Med"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/jat\/bkz063","volume":"43","author":"Mei V.","year":"2019","unstructured":"Mei V.; Concheiro M.; Pardi J.; Cooper G.; Validation of an LC-MS\/MS Method for the Quantification of 13 Designer Benzodiazepines in Blood. J Anal Toxicol 2019,43(9),688-695","journal-title":"J Anal Toxicol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11062-014-9429-2","volume":"46","author":"Golovenko N.Y.","year":"2014","unstructured":"Golovenko N.Y.; Larionov V.B.; Pharmacodynamical and neuroreceptor analysis of the permeability of the blood-brain barrier for Derivatives of 1, 4-Benzodiazepine. Neurophysiology 2014,46(3),199-205","journal-title":"Neurophysiology"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/00498250701834665","volume":"38","author":"Hallifax D.","year":"2008","unstructured":"Hallifax D.; Galetin A.; Houston J.B.; Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 2008,38(4),353-367","journal-title":"Xenobiotica"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1021\/jm00339a010","volume":"6","author":"Sternbach L.H.","year":"1963","unstructured":"Sternbach L.H.; Fryer R.I.; Keller O.; Metlesics W.; Sach G.; Steiger N.; Quinazolines and 1, 4-Benzodiazepines. X. 1 Nitro-Substituted 5-Phenyl-1, 4-benzodiazepine Derivatives2. J Med Chem 1963,6(3),261-265","journal-title":"J Med Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/ac60365a037","volume":"48","author":"de Silva J.A.","year":"1976","unstructured":"de Silva J.A.; Bekersky I.; Puglisi C.V.; Brooks M.A.; Weinfeld R.E.; Determination of 1,4-benzodiazepines and -diazepin-2-ones in blood by electron-capture gas-liquid chromatography. Anal Chem 1976,48(1),10-19","journal-title":"Anal Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/jm00004a017","volume":"38","author":"Maddalena D.J.","year":"1995","unstructured":"Maddalena D.J.; Johnston G.A.; Prediction of receptor properties and binding affinity of ligands to benzodiazepine\/GABAA receptors using artificial neural networks. J Med Chem 1995,38(4),715-724","journal-title":"J Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1021\/jm960536o","volume":"39","author":"So S.S.","year":"1996","unstructured":"So S.S.; Karplus M.; Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine\/GABAA receptors. J Med Chem 1996,39(26),5246-5256","journal-title":"J Med Chem"},{"key":"ref=135","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol, 2017. Annual Report on the Implementation of Council Decision 2005\/387\/JHA (2017). Lisbon, Portugal"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/164_2018_154","volume":"252","author":"Moosmann B.","year":"2018","unstructured":"Moosmann B.; Auw\u00e4rter V.; Designer Benzodiazepines: Another Class of New Psychoactive Substances. Handb Exp Pharmacol 2018,252,383-410","journal-title":"Handb Exp Pharmacol"},{"key":"ref=137","author":"Earl R.","unstructured":"Earl R.; Henryk S.L.;  inventors; Hoffmann, La Roche, assignee. Amino substituted benzophenone oximes and derivatives thereof. United States patent US 3,136,815."},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0006-8993(84)90013-1","volume":"310","author":"Skerritt J.H.","year":"1984","unstructured":"Skerritt J.H.; Werz M.A.; McLean M.J.; Macdonald R.L.; Diazepam and its anomalous p-chloro-derivative Ro 5-4864: comparative effects on mouse neurons in cell culture. Brain Res 1984,310(1),99-105","journal-title":"Brain Res"},{"key":"ref=139","first-page":"61","volume":"225","author":"Schoemaker H.","year":"1983","unstructured":"Schoemaker H.; Boles R.G.; Horst W.D.; Yamamura H.I.; Specific high-affinity binding sites for [3H]Ro 5-4864 in rat brain and kidney. J Pharmacol Exp Ther 1983,225(1),61-69","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=140","first-page":"26","volume":"22","author":"Marangos P.J.","year":"1982","unstructured":"Marangos P.J.; Patel J.; Boulenger J.P.; Clark-Rosenberg R.; Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864. Mol Pharmacol 1982,22(1),26-32","journal-title":"Mol Pharmacol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0014-2999(03)01789-8","volume":"471","author":"Gavioli E.C.","year":"2003","unstructured":"Gavioli E.C.; Duarte F.S.; Bressan E.; Ferrara P.; Farges R.C.; De Lima T.C.; Antidepressant-like effect of Ro5-4864, a peripheral-type benzodiazepine receptor ligand, in forced swimming test. Eur J Pharmacol 2003,471(1),21-26","journal-title":"Eur J Pharmacol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000075547","volume":"70","author":"DalB\u00f3 S.","year":"2004","unstructured":"DalB\u00f3 S.; Nardi G.M.; Ferrara P.; Ribeiro-do-Valle R.M.; Farges R.C.; Antinociceptive effects of peripheral benzodiazepine receptors. Pharmacology 2004,70(4),188-194","journal-title":"Pharmacology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.mad.2005.06.001","volume":"126","author":"Leonelli E.","year":"2005","unstructured":"Leonelli E.; Yague J.G.; Ballabio M.; Azcoitia I.; Magnaghi V.; Schumacher M.; Garcia-Segura L.M.; Melcangi R.C.; Ro5-4864, a synthetic ligand of peripheral benzodiazepine receptor, reduces aging-associated myelin degeneration in the sciatic nerve of male rats. Mech Ageing Dev 2005,126(11),1159-1163","journal-title":"Mech Ageing Dev"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.yjmcc.2014.09.024","volume":"78","author":"Solhjoo S.","year":"2015","unstructured":"Solhjoo S.; O\u2019Rourke B.; Mitochondrial instability during regional ischemia-reperfusion underlies arrhythmias in monolayers of cardiomyocytes. J Mol Cell Cardiol 2015,78,90-99","journal-title":"J Mol Cell Cardiol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jnr.20430","volume":"80","author":"Veiga S.","year":"2005","unstructured":"Veiga S.; Azcoitia I.; Garcia-Segura L.M.; Ro5-4864, a peripheral benzodiazepine receptor ligand, reduces reactive gliosis and protects hippocampal hilar neurons from kainic acid excitotoxicity. J Neurosci Res 2005,80(1),129-137","journal-title":"J Neurosci Res"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1460-9568.2008.06065.x","volume":"27","author":"Mills C.","year":"2008","unstructured":"Mills C.; Makwana M.; Wallace A.; Benn S.; Schmidt H.; Tegeder I.; Costigan M.; Brown R.H.; Raivich G.; Woolf C.J.; Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats. Eur J Neurosci 2008,27(4),937-946","journal-title":"Eur J Neurosci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.expneurol.2008.08.008","volume":"214","author":"Soustiel J.F.","year":"2008","unstructured":"Soustiel J.F.; Zaaroor M.; Vlodavsky E.; Veenman L.; Weizman A.; Gavish M.; Neuroprotective effect of Ro5-4864 following brain injury. Exp Neurol 2008,214(2),201-208","journal-title":"Exp Neurol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jsbmb.2017.04.010","volume":"171","author":"Arbo B.D.","year":"2017","unstructured":"Arbo B.D.; Hoppe J.B.; Rodrigues K.; Garcia-Segura L.M.; Salbego C.G.; Ribeiro M.F.; 4\u2032-Chlorodiazepam is neuroprotective against amyloid-beta in organotypic hippocampal cultures. J Steroid Biochem Mol Biol 2017,171,281-287","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=149","doi-asserted-by":"publisher","DOI":"10.1177\/1744806917748019","volume":"14","author":"Ma B.","year":"2018","unstructured":"Ma B.; Liu X.; Huang X.; Ji Y.; Jin T.; Ma K.; Translocator protein agonist Ro5-4864 alleviates neuropathic pain and promotes remyelination in the sciatic nerve. Mol Pain 2018,14","journal-title":"Mol Pain"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/FTD.0000000000000557","volume":"40","author":"Ameline A.","year":"2018","unstructured":"Ameline A.; Arbouche N.; Raul J.S.; Kintz P.; Documentation of a little-studied designer benzodiazepine after a controlled single administration: ii. concentration profile of deschloroetizolam in saliva. Ther Drug Monit 2018,40(6),759-761","journal-title":"Ther Drug Monit"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/dta.2561","volume":"11","author":"Moosmann B.","year":"2019","unstructured":"Moosmann B.; Bisel P.; Westphal F.; Wilde M.; Kempf J.; Angerer V.; Auw\u00e4rter V.; Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4\u2032-chlorodiazepam (Ro5-4864). Drug Test Anal 2019,11(3),541-549","journal-title":"Drug Test Anal"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dta.2211","author":"Manchester K.R.","year":"2017","unstructured":"Manchester K.R.; Lomas E.C.; Waters L.; Dempsey F.C.; Maskell P.D.; The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test Anal 2017,1-17","journal-title":"Drug Test Anal"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1021\/jm00197a021","volume":"22","author":"Hester J.B.","year":"1979","unstructured":"Hester J.B.; Von Voigtlander P.; 6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity. J Med Chem 1979,22(11),1390-1398","journal-title":"J Med Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/dta.1484","volume":"5","author":"Vogt S.","year":"2013","unstructured":"Vogt S.; Kempf J.; Buttler J.; Auw\u00e4rter V.; Weinmann W.; Desalkylflurazepam found in patients\u2019 samples after high-dose midazolam treatment. Drug Test Anal 2013,5(9-10),745-747","journal-title":"Drug Test Anal"},{"key":"ref=155","author":"Maskell P.D.","year":"2019","unstructured":"Maskell P.D.; Wilson N.E.;  Handbook of Novel Psychoactive Substances: What Clinicians Should Know about NPS 978-1-138-\n06830-8 2019","journal-title":"Handbook of Novel Psychoactive Substances: What Clinicians Should Know about NPS"},{"key":"ref=156","author":"Akatsu M.","year":"1972","unstructured":"Akatsu M.; Benzodiazepine derivatives. Jpn Kokai Tokkyo Koho, JP 47030683 B 19721109. 1972","journal-title":"Jpn Kokai Tokkyo Koho,"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/(SICI)1521-3838(199801)17:01<14:AID-QSAR14>3.0.CO;2-U","volume":"17","author":"Winkler A.D.","year":"1998","unstructured":"Winkler A.D.; Burden F.R.; Watkins A.J.R.; Atomistic topological indices applied to benzodiazepines using various regression methods. Quantitative Structure-Activity Relationships 1998,17(1),14-19","journal-title":"Quantitative Structure-Activity Relationships"},{"key":"ref=158","author":"Reeder E.","unstructured":"Reeder E.; inventor. Process for preparing 5-phenyl-1,2-dihydro-\n3H-1,4-benzodiazepines. United States patent US 3,109,843, 1963 Nov;5."},{"key":"ref=159","first-page":"3375","volume":"19","author":"Anjaneyulu Y.","year":"2007","unstructured":"Anjaneyulu Y.; Marayya D.; Linga R.D.; Krishna R.P.; High performance thin layer chromatographic determination of the related substances in alprazolam drug. Asian J Chem 2007,19(5),3375","journal-title":"Asian J Chem"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3762\/bjoc.7.57","volume":"7","author":"Baumann M.","year":"2011","unstructured":"Baumann M.; Baxendale I.R.; Ley S.V.; Nikbin N.; An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals. Beilstein J Org Chem 2011,7,442-495","journal-title":"Beilstein J Org Chem"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0021-9673(00)01177-8","volume":"910","author":"Borrey D.","year":"2001","unstructured":"Borrey D.; Meyer E.; Lambert W.; Van Calenbergh S.; Van Peteghem C.; De Leenheer A.P.; Sensitive gas chromatographic--mass spectrometric screening of acetylated benzodiazepines. J Chromatogr A 2001,910(1),105-118","journal-title":"J Chromatogr A"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jat\/25.4.250","volume":"25","author":"Wilhelm M.","year":"2001","unstructured":"Wilhelm M.; Battista H.J.; Obendorf D.; HPLC with simultaneous UV and reductive electrochemical detection at the hanging mercury drop electrode: a highly sensitive and selective tool for the determination of benzodiazepines in forensic samples. J Anal Toxicol 2001,25(4),250-257","journal-title":"J Anal Toxicol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jchromb.2006.01.009","volume":"832","author":"Bugey A.","year":"2006","unstructured":"Bugey A.; Rudaz S.; Staub C.; A fast LC-APCI\/MS method for analyzing benzodiazepines in whole blood using monolithic support. J Chromatogr B Analyt Technol Biomed Life Sci 2006,832(2),249-255","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1254\/fpj.73.243","volume":"73","author":"Ueki S.","year":"1977","unstructured":"Ueki S.; Gomita Y.; Ataki Y.; Yamada K.; Yoshimura H.; Behavioral effects of 5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one (ID-690). Nippon Yakurigaku Zasshi 1977,73(2),243-255","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1254\/fpj.73.123","volume":"73","author":"Fukuda H.","year":"1977","unstructured":"Fukuda H.; Kudo Y.; Ono H.; Togari A.; Tanaka Y.; Pharmacological study on 5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one (ID-690), with special reference to the effects on motor systems. Nippon Yakurigaku Zasshi 1977,73(1),123-134","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1254\/fpj.75.315","volume":"75","author":"Fukuda H.","year":"1979","unstructured":"Fukuda H.; Kudo Y.; Takeuchi E.; Effects of benzodiazepine derivatives on \u03b3-motor system in rats (author\u2019s transl). Nippon Yakurigaku Zasshi 1979,75(4),315-319","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1254\/fpj.70.531","volume":"70","author":"Watanabe S.","year":"1974","unstructured":"Watanabe S.; Kawasaki H.; Nishi H.; Ueki S.; Electroencephalographic effects of ID-690 [5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one] in rabbits with chronic electrode implants. Nippon Yakurigaku Zasshi 1974,70(4),531-542","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1254\/fpj.73.437","volume":"73","author":"Tsuchiya T.","year":"1977","unstructured":"Tsuchiya T.; Fukushima H.; Effects of 5-(o-chlorophenyl)-1-methyl-7-nitro-1, 3-dihydro-2HO1, 4-benzodiazepin-2-one (ID-390) as compared to nitrazepam on the sleep-wakefulness cycle in cats (author\u2019s transl). Nippon Yakurigaku Zasshi 1977,73(4),437-447","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=169","author":"Hellerbach J.","unstructured":"Hellerbach J.;  Thienotriazolodiazepine. 1974. DE 2405682. Hoffmann-La Roche Inc. (Accessed Oct 7, 2019)"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","volume":"73","author":"Zawilska J.B.","year":"2019","unstructured":"Zawilska J.B.; Wojcieszak J.; An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology 2019,73,8-16","journal-title":"Neurotoxicology"},{"key":"ref=171","unstructured":"ukchemicalresearch.org(Accessed Oct 7, 2019)"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1081\/JLC-100101693","volume":"22","author":"Zsila F.","year":"1999","unstructured":"Zsila F.; Gergely A.; Horvath P.; Szasz G.; Separation and identification of tofisopam stereoisomers by hyphenated HPLC-CD technique. J Liq Chrom Relat Tech 1999,22(5),713-719","journal-title":"J Liq Chrom Relat Tech"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/elps.201800220","volume":"39","author":"Foroughbakhshfasaei M.","year":"2018","unstructured":"Foroughbakhshfasaei M.; Szab\u00f3 Z.I.; Mirzahosseini A.; Horv\u00e1th P.; T\u00f3th G.; Enantiomeric quality control of R-Tofisopam by HPLC using polysaccharide-type chiral stationary phases in polar organic mode. Electrophoresis 2018,39(20),2566-2574","journal-title":"Electrophoresis"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF00542458","volume":"22","author":"Bond A.","year":"1982","unstructured":"Bond A.; Lader M.; A comparison of the psychotropic profiles of tofisopam and diazepam. Eur J Clin Pharmacol 1982,22(2),137-142","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.2174\/092986708786848488","volume":"15","author":"Bernard P.","year":"2008","unstructured":"Bernard P.; Dufresne-Favetta C.; Favetta P.; Do Q.T.; Himbert F.; Zubrzycki S.; Scior T.; Lugnier C.; Application of drug repositioning strategy to TOFISOPAM. Curr Med Chem 2008,15(30),3196-3203","journal-title":"Curr Med Chem"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4103\/0253-7613.169593","volume":"47","author":"Murthy V.S.","year":"2015","unstructured":"Murthy V.S.; Mangot A.G.; Psychiatric aspects of phosphodiesterases: An overview. Indian J Pharmacol 2015,47(6),594-599","journal-title":"Indian J Pharmacol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3164\/jcbn.15-140","volume":"58","author":"Tominaga K.","year":"2016","unstructured":"Tominaga K.; Fujikawa Y.; Tsumoto C.; Kadouchi K.; Tanaka F.; Kamata N.; Yamagami H.; Tanigawa T.; Watanabe T.; Fujiwara Y.; Arakawa T.; Disorder of autonomic nervous system and its vulnerability to external stimulation in functional dyspepsia. J Clin Biochem Nutr 2016,58(2),161-165","journal-title":"J Clin Biochem Nutr"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0149-7634(86)90026-6","volume":"10","author":"Pellow S.","year":"1986","unstructured":"Pellow S.; File S.E.; Is tofisopam an atypical anxiolytic? Neurosci Biobehav Rev 1986,10(2),221-227","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=179","first-page":"79","volume":"63","author":"Pet\u00f3cz L.","year":"1993","unstructured":"Pet\u00f3cz L.; Pharmacologic effects of tofizopam (Grandaxin). Acta Pharm Hung 1993,63(2),79-82","journal-title":"Acta Pharm Hung"},{"key":"ref=180","first-page":"154","volume":"17","author":"Srivastava S.","year":"2014","unstructured":"Srivastava S.; Bhatia M.S.; Gupta K.; Rajdev K.; Current update on evidence based literature of tofisopam. Delhi Psychiatry J 2014,17,154-159","journal-title":"Delhi Psychiatry J"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.2042-7158.1985.tb05003.x","volume":"37","author":"Chopin P.","year":"1985","unstructured":"Chopin P.; Stenger A.; Couzinier J.P.; Briley M.; Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. J Pharm Pharmacol 1985,37(12),917-919","journal-title":"J Pharm Pharmacol"},{"key":"ref=182","first-page":"91","volume":"63","author":"Szeg\u00f3 J.","year":"1993","unstructured":"Szeg\u00f3 J.; Somogyi M.; Papp E.; Excerpts from the clinical pharmacologic and clinical studies of Grandaxin. Acta Pharm Hung 1993,63(2),91-98","journal-title":"Acta Pharm Hung"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00702-010-0507-3","volume":"117","author":"Rundfeldt C.","year":"2010","unstructured":"Rundfeldt C.; Soca\u0142a K.; Wla\u017a P.; The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna) 2010,117(11),1319-1325","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1016\/j.bmcl.2011.08.036","volume":"21","author":"Bihel F.J.","year":"2011","unstructured":"Bihel F.J.; Justiniano H.; Schmitt M.; Hellal M.; Ibrahim M.A.; Lugnier C.; Bourguignon J.J.; New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. Bioorg Med Chem Lett 2011,21(21),6567-6572","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=185","first-page":"21","author":"Vakhrushev IaM.","year":"2004","unstructured":"Vakhrushev IaM.; Belova E.V.; Efremova L.I.; Use of grandaxine in the treatment of patients with erosive-ulcerative stomach and gastroduodenal lesions. Eksp Klin Gastroenterol 2004(4),21-24","journal-title":"Eksp Klin Gastroenterol"},{"key":"ref=186","first-page":"65","author":"Plotnikova E.Iu.","year":"2005","unstructured":"Plotnikova E.Iu.; Beloborodova E.I.; Use of grandaxin in hypermotor dysfunction of the biliary ducts in young people. Eksp Klin\nGastroenterol, 113-114.2005(6),65-70","journal-title":"Eksp Klin\nGastroenterol,"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2036.2007.03566.x","volume":"27","author":"Leventer S.M.","year":"2008","unstructured":"Leventer S.M.; Raudibaugh K.; Frissora C.L.; Kassem N.; Keogh J.C.; Phillips J.; Mangel A.W.; Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008,27(2),197-206","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11894-010-0124-1","volume":"12","author":"Manabe N.","year":"2010","unstructured":"Manabe N.; Rao A.S.; Wong B.S.; Camilleri M.; Emerging pharmacologic therapies for irritable bowel syndrome. Curr Gastroenterol Rep 2010,12(5),408-416","journal-title":"Curr Gastroenterol Rep"},{"key":"ref=189","first-page":"83","volume":"63","author":"Klebovich I.","year":"1993","unstructured":"Klebovich I.; Abermann M.; Pharmacokinetics and metabolism of tofizopam (Grandaxin). Acta Pharm Hung 1993,63(2),83-90","journal-title":"Acta Pharm Hung"},{"key":"ref=190","first-page":"423","volume":"36","author":"Tomori E.","year":"1984","unstructured":"Tomori E.; Elekes I.; L\u00e1ng T.; Horv\u00e1th G.; Investigation of metabolites of tofizopam in man and animals. Pol J Pharmacol Pharm 1984,36(4),423-430","journal-title":"Pol J Pharmacol Pharm"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2174\/1574884710666150126143421","volume":"10","author":"Hatayama M.","year":"2015","unstructured":"Hatayama M.; Sumida C.; Kurajoh M.; Shiraishi J.; Okazaki H.; Shoji T.; Koyama H.; Tsutsumi Z.; Moriwaki Y.; Namba M.; Yamamoto T.; Acute effects of oral tofisopam on plasma concentration and urinary excretion of uric acid and oxypurinol \u201cpreliminary communication\u201d. Curr Clin Pharmacol 2015,10(2),160-164","journal-title":"Curr Clin Pharmacol"},{"key":"ref=192","first-page":"41","volume":"77","author":"Ve\u012dn A.V.","year":"1999","unstructured":"Ve\u012dn A.V.; Artemenko A.R.; Oknin V.Iu.; Pomortseva I.V.; Effectiveness of grandaxin in the treatment of somatoform disorders. Klin Med (Mosk) 1999,77(6),41-45","journal-title":"Klin Med (Mosk)"},{"key":"ref=193","first-page":"23","volume":"72","author":"Osipenko M.F.","year":"2000","unstructured":"Osipenko M.F.; Khramov IuA.; Makarova T.A.; Vdovenko E.G.; Role of grandaxin in the treatment of functional gastrointestinal diseases. Ter Arkh 2000,72(10),23-27","journal-title":"Ter Arkh"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1248\/yakushi.123.365","volume":"123","author":"Kato R.","year":"2003","unstructured":"Kato R.; Ooi K.; Ueno K.; A case in which tofisopam was effective for treatment of paroxysmal supraventricular tachycardia. Yakugaku Zasshi 2003,123(5),365-368","journal-title":"Yakugaku Zasshi"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/11080583","volume":"11","author":"Fustero S.","year":"2006","unstructured":"Fustero S.; Gonz\u00e1lez J.; del Pozo C.; 1,4-Benzodiazepine N nitrosoamidines: useful intermediates in the synthesis of tricyclic benzodiazepines. Molecules 2006,11(8),583-588","journal-title":"Molecules"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0021-9673(92)80150-S","volume":"609","author":"Kaliszan R.","year":"1992","unstructured":"Kaliszan R.; Kaliszan A.; Noctor T.A.; Purcell W.P.; Wainer I.W.; Mechanism of retention of benzodiazepines in affinity, reversed-phase and adsorption high-performance liquid chromatography in view of quantitative structure retention relationships. J Chromatogr A 1992,609(1-2),69-81","journal-title":"J Chromatogr A"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2165\/00003088-198916060-00002","volume":"16","author":"Garzone P.D.","year":"1989","unstructured":"Garzone P.D.; Kroboth P.D.; Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989,16(6),337-364","journal-title":"Clin Pharmacokinet"},{"key":"ref=198","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-019-00501-1","author":"Qian Z.","year":"2019","unstructured":"Qian Z.; Liu C.; Huang J.; Deng Q.; Hua Z.; Identification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case. Forensic Toxicol 2019","journal-title":"Forensic Toxicol"},{"key":"ref=199","unstructured":"Drug-caf\u00e9"},{"key":"ref=200","unstructured":"(Accessed Oct 8, 2019)"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1135\/cccc19831477","volume":"48","author":"Vejdelek Z.","year":"1983","unstructured":"Vejdelek Z.; Protiva M.; Synthesis of two 1-substituted 8-bromo-6-(2-chlorophenyl)-4H-s-triazolo[4,3-a]-1,4-benzodiazepines. Collect Czech Chem Commun 1983,48(5),1477-1482","journal-title":"Collect Czech Chem Commun"},{"key":"ref=202","first-page":"482","volume":"24","author":"Gonzalez L\u00f3pez F.","year":"1986","unstructured":"Gonzalez L\u00f3pez F.; Mari\u00f1o E.L.; Dominguez-Gil A.; Pharmacokinetics of tiadipone: a new anxiolytic. Int J Clin Pharmacol Ther Toxicol 1986,24(9),482-484","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"ref=203","unstructured":"CIMA. Medicine Online Information Center of AEMPS (from the Spanish: Centro de Informaci\u00f3n Online de Medicamentos de la Agencia espa\u00f1ola de medicamentos y productos sanitarios). (Accessed Oct 8,\n2019)"},{"key":"ref=204","unstructured":"Tiadipona \u00ae Summary of Product Characteristics (in Spanish)."},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S0140-6736(94)92065-6","volume":"343","author":"Andrade R.J.","year":"1994","unstructured":"Andrade R.J.; Lucena M.I.; Alcantara R.; Fraile J.M.; Bentazepam-associated chronic liver disease. Lancet 1994,343(8901),860","journal-title":"Lancet"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/00004836-199712000-00042","volume":"25","author":"de-la-Serna C.","year":"1997","unstructured":"de-la-Serna C.; Gil-Grande L.A.; Sanrom\u00e1n A.L.; Gonzalez M.; Ruiz-del-Arbol L.; Garcia Plaza A.; Bentazepam-induced hepatic bridging necrosis. J Clin Gastroenterol 1997,25(4),710-711","journal-title":"J Clin Gastroenterol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1023\/A:1005520523502","volume":"45","author":"Andrade R.J.","year":"2000","unstructured":"Andrade R.J.; Lucena M.I.; Aguilar J.; Lazo M.D.; Camargo R.; Moreno P.; Garc\u00eda-Esca\u00f1o M.D.; Marquez A.; Alc\u00e1ntara R.; Alc\u00e1in G.; Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Dig Dis Sci 2000,45(7),1400-1404","journal-title":"Dig Dis Sci"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1157\/13047311","volume":"120","author":"Andrade R.J.","year":"2003","unstructured":"Andrade R.J.; L\u00f3pez-Torres E.; Lucena M.I.; Fern\u00e1ndez, Mdel.C. Acute hepatitis due to bentazepam. Med Clin (Barc) 2003,120(17),678-679","journal-title":"Med Clin (Barc)"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/hep.21424","volume":"44","author":"Andrade R.J.","year":"2006","unstructured":"Andrade R.J.; Lucena M.I.; Kaplowitz N.; Garc\u00eda-Mu\u0146oz B.; Borraz Y.; Pachkoria K.; Garc\u00eda-Cort\u00e9s M.; Fern\u00e1ndez M.C.; Pelaez G.; Rodrigo L.; Dur\u00e1n J.A.; Costa J.; Planas R.; Barriocanal A.; Guarner C.; Romero-Gomez M.; Mu\u0146oz-Yag\u00fce T.; Salmer\u00f3n J.; Hidalgo R.; Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006,44(6),1581-1588","journal-title":"Hepatology"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2045125314559539","volume":"5","author":"Baumeister D.","year":"2015","unstructured":"Baumeister D.; Tojo L.M.; Tracy D.K.; Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol 2015,5(2),97-132","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20174","volume":"14","author":"Schifano F.","year":"2015","unstructured":"Schifano F.; Orsolini L.; Duccio P.G.; Corkery J.M.; Novel psychoactive substances of interest for psychiatry. World Psychiatry 2015,14(1),15-26","journal-title":"World Psychiatry"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1373\/jalm.2017.025387","volume":"3","author":"Pope J.D.","year":"2018","unstructured":"Pope J.D.; Choy K.W.; Drummer O.H.; Schneider H.G.; Novel benzodiazepines (clonazolam and flubromazolam) identified in candy-like pills. J Appl Lab Med 2018,3(1),48-55","journal-title":"J Appl Lab Med"},{"key":"ref=213","first-page":"214","volume":"13","author":"Griffin C.E.","year":"2013","unstructured":"Griffin C.E.; Kaye A.M.; Bueno F.R.; Kaye A.D.; Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013,13(2),214-223","journal-title":"Ochsner J"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.forsciint.2016.02.033","volume":"262","author":"Bros\u00e9us J.","year":"2016","unstructured":"Bros\u00e9us J.; Gentile N.; Esseiva P.; The Cutting of Cocaine and Heroin: A Critical Review. For Sci Intern, 2016,262,73-83","journal-title":"For Sci Intern,"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00414-017-1541-6","volume":"131","author":"El Balkhi S.","year":"2017","unstructured":"El Balkhi S.; Chaslot M.; Picard N.; Dulaurent S.; Delage M.; Mathieu O.; Saint-Marcoux F.; Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int J Legal Med 2017,131(4),979-988","journal-title":"Int J Legal Med"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1089\/cyber.2014.0486","volume":"18","author":"Orsolini L.","year":"2015","unstructured":"Orsolini L.; Papanti G.D.; Francesconi G.; Schifano F.; Mind navigators of chemicals\u2019 experimenters? A web-based description of e-psychonauts. Cyberpsychol Behav Soc Netw 2015,18(5),296-300","journal-title":"Cyberpsychol Behav Soc Netw"},{"key":"ref=217","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2566","volume":"32","author":"Corkery J.M.","year":"2017","unstructured":"Corkery J.M.; Orsolini L.; Papanti D.; Schifano F.; From concept(\nion) to life after death\/the grave: The \u2018natural\u2019 history and life\ncycle(s) of novel psychoactive substances (NPS). Hum Psychopharmacol, Review.2017,32(3)","journal-title":"Hum Psychopharmacol,"},{"key":"ref=218","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2573","volume":"32","author":"Orsolini L.","year":"2017","unstructured":"Orsolini L.; Papanti D.; Corkery J.; Schifano F.; An insight into the deep web; why it matters for addiction psychiatry? Hum Psychopharmacol 2017,32(3)","journal-title":"Hum Psychopharmacol"},{"key":"ref=219","first-page":"A4900","volume":"155","author":"Vinkers C.H.","year":"2012","unstructured":"Vinkers C.H.; Tijdink J.K.; Luykx J.J.; Vis R.; Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics. Ned Tijdschr Geneeskd 2012,155(35),A4900","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/da.22771","volume":"35","author":"Turner S.","year":"2018","unstructured":"Turner S.; Mota N.; Bolton J.; Sareen J.; Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature. Depress Anxiety 2018,35(9),851-860","journal-title":"Depress Anxiety"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","volume":"125","author":"Jones J.D.","year":"2012","unstructured":"Jones J.D.; Mogali S.; Comer S.D.; Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012,125(1-2),8-18","journal-title":"Drug Alcohol Depend"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X18666200110121333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178254\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X18666200110121333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T10:21:38Z","timestamp":1655374898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178254\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":221,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200110121333","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}